AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Jun 02, 2025

Thought-provoking takeaways from AUA2025

A broad spectrum of urology research and expertise is available on demand.


Getty Images 2212620732

There was no shortage of timely topics, expert guidance and clinical research on display at the 2025 AUA Annual Meeting, as highlighted in the AUA2025: Key Takeaways sessions on the last day.

The session “AUA2025: Key Takeaways: Thought-Provoking Discussions With the Experts” featured rapid-fire discussion and clinically significant abstracts from eight broader topics, ranging from prostate oncology to lower urinary tract reconstruction, to shine a light on cutting-edge developments.

Among the highlights of the session was a transformative moment in the management of benign prostatic hyperplasia (BPH), with experts highlighting a surge in innovation, real-world data integration, and a growing emphasis on patient-centered outcomes. Speakers Dean Elterman, MD, MSc, FRCSC, an associate professor of urology at the University of Toronto in Canada, and Bilal Chughtai, MD, an associate professor of urology at Weill Cornell Medicine in New York, said the field is generating “excitement and innovation,” particularly in the move from research to clinical practice.

“BPH is one of those areas that has a lot of gizmos and gadgets, and I think it's an exciting time to be in the field and certainly on the surgical side of things,” Dr. Elterman said.

The session opened with a reflection on the sheer volume of research presented—over 100 abstracts focused on BPH—underscoring a field rich with innovation.

“We’re seeing a renaissance in BPH treatment,” said Dr. Elterman. “From novel stents to real-world evidence, the landscape is evolving rapidly.”

One of the session’s key themes was the validation of clinical trial outcomes through real-world data. For example, the AUA’s AQUA registry, encompassing over 1.6 million men, revealed that minimally invasive therapies are delivering consistent results outside of controlled trials. However, the presenters also noted a critical gap: Only 14% of patients had complete symptom score data, limiting the depth of analysis.

A highlight of the session was the presentation of the IMPACT randomized trial, comparing the UroLift® prostatic urethral lift to tamsulosin, a common alpha blocker. The results were striking. UroLift® patients saw a 40%-46% improvement in symptoms at one and three months, compared to just 15%-18% in the medication group. Additionally, the UroLift® was able to preserve or improve sexual function, while the medication group experienced declines.

“This is the kind of data that reshapes clinical practice,” Dr. Chughtai said. “Patients want more than symptom relief—they want quality of life.”

The session underscored the fact that the field of BPH treatment is rapidly evolving with a growing arsenal of minimally invasive and patient-friendly options. The focus is shifting toward early intervention, real-world validation, and preserving quality of life.

The session also featured in-depth discussion of female urinary health. During “Key Takeaways from AUA2025: Female Urology,” speakers Mitch Goldenberg, MD, FPMRS, and Kathleen Kobashi, MD, spotlighted groundbreaking research, novel technologies, and evolving clinical guidelines that promise to reshape care for women with complex urological conditions. Dr. Goldenberg is an assistant professor of clinical urology at the University of Southern California’s Keck School of Medicine in Los Angeles, and Dr. Kobashi, MD, is a professor of clinical urology at Weill Cornell Medical College in New York.

Among their discussions was a look at expanding sacral neuromodulation to neurogenic patients. Traditionally reserved for non-neurogenic bladder patients, sacral neuromodulation is now showing promise in those with neurogenic bladder conditions. Referencing one retrospective study of 275 patients, Drs. Goldenberg and Kobashi said the study revealed comparable outcomes between neurogenic and nonneurogenic groups, particularly among those with nonprogressive neurological diseases. With the advent of MRI-compatible implants, this therapy may soon become more accessible to a broader patient population.

“This could crack the nut wide open,” Dr. Kobashi said, emphasizing the potential for expanded treatment options.

Moving on to the topic of pelvic organ prolapse, Dr. Goldenberg introduced a study that he said personally challenged his notion about when patients should receive mesh. The study challenged long-held beliefs about mesh placement during hysterectomy and found that mesh exposure rates remained low—even in patients undergoing radical procedures or with prior pelvic radiation. With only an 11% failure rate over eight years and minimal need for reoperation, the findings support reconsidering mesh use during initial surgeries rather than delaying intervention.

The session continued, covering everything from brain imaging to immunotherapy and microbiome science. Drs. Goldenberg and Kobashi underscored a future rich with innovation and compassion in the field of female urinary health.

“We’re not just treating symptoms—we’re transforming lives,” Dr. Kobashi said. 

All eight Key Takeaway presentations with slides are available on demand until Aug. 31, 2025.

  • BPH/Male LUTS
  • Oncology: Prostate
  • Oncology: Bladder
  • Oncology: Kidney
  • Sexual Dysfunction
  • Endourology/Stones
  • Female Urology
  • Lower Urinary Tract Reconstruction
Interesting Stories
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
More Content
Getty Images 1203616323
Guidelines
Guidelines offer new directions in urological care
Jun 02, 2025
Getty Images 1397381715
Meeting Coverage
P2s at AUA2025: Clinical trials reshaping urology
Jun 02, 2025
Vin Gupta, MD, MPA
Meeting Coverage
Keynote call to action: Rethinking innovation in urology
Jun 02, 2025
K4 0795
Meeting Coverage
Meet your 2025 AUA Residents Bowl champions!
Jun 02, 2025
Siobhan Hartigan, MD
Meeting Coverage
Healthy debates
Jun 02, 2025
Dr. David Penson (fourth from left) and first-place winner (small program) Cedars-Sinai Urology Residency Program.
Meeting Coverage
Olympic gold
Jun 02, 2025
Mg 1067 is0 U4 Ai31z Copy
Meeting Coverage
Picture this
Jun 02, 2025
Getty Images 1356620786
Meeting Coverage
Save the date for AUA2026
Jun 02, 2025
Aua Readit xd2d B Aih Gz Copy
Meeting Coverage
Did you miss something?
Jun 02, 2025
Getty Images 1285476518
Meeting Coverage
AUA2025: By the numbers
May 13, 2025
Getty Images 2196976767
Meeting Coverage
Claim your CME
May 13, 2025
Getty Images 1422478091
Meeting Coverage
AUA2025 on demand
May 13, 2025
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.